Satoko Shiotani

Satoko Shiotani

Auto-generated profile, based on publicly available information

Satoko Shiotani

Department of Breast Oncology, National Kyushu Cancer Center, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in Transplantation
Verified
Journal Article
Closed access
SSSatoko Shiotani
Satoko Shiotani
MSMitsuo Shimada
Mitsuo Shimada
TSTaketoshi Suehiro
Taketoshi Suehiro
YSYuji Soejima
Yuji Soejima
TYTomoharu Yosizumi
Tomoharu Yosizumi
YMYoshihiko Maehara
Yoshihiko Maehara
Reperfusion of ischemic tissues is known to cause the generation of reactive oxygen species (ROS) with resultant tissue damage. However, the sources of ROS in reperfused tissues are not fully characterized. We hypothesized that the small GTPase Rho and its target effector Rho-kinase/ROK/ROCK are involved in the oxidative burst in reperfused tissue with resultant reperfusion injury. In an in vivo rat model of liver transplantation using cold ischemia for 12 hr followed by reperfusion, a specific Rho-kinase inhibitor, fasudil (30 mg/kg), was administered orally 1 hr before the transplantation. Fasudil suppressed the ischemia-reperfusion (I/R)-induced generation of ROS after reperfusion (P<0.01) and also suppressed the release of inflammatory cytokines (tumor necrosis factor-α, interleukin-1β) 3 hr after reperfusion, resulting in a significant reduction of I/R-induced hepatocellular injury (P<0.05), necrosis, apoptosis (P<0.01), and neutrophil infiltration (P<0.0001) 12 hr after reperfusion. All animals receiving a graft without fasudil died within 3 days, whereas 40% of those receiving fasudil survived (P<0.001). The present study demonstrates that Rho-kinase–mediated production of ROS and inflammatory cytokines are substantially involved in the pathogenesis of hepatocellular necrosis and apoptosis induced by cold I/R in vivo and that Rho-kinase may be regarded as a novel therapeutic target for the disorder.

18 May 2004
Verified
Journal Article
Closed access
MSMitsuo Shimada
Mitsuo Shimada
HIHideki Ijichi
Hideki Ijichi
YYYusuke Yonemura
Yusuke Yonemura
NHNoboru Harada
Noboru Harada
SSSatoko Shiotani
Satoko Shiotani
YMYoshihiko Maehara
Yoshihiko Maehara

31 March 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HSHideo Shigematsu
Hideo Shigematsu
HKHidetoshi Kawaguchi
Hidetoshi Kawaguchi
YNYoshiaki Nakamura
Yoshiaki Nakamura
KTKimihiro Tanaka
Kimihiro Tanaka
SSSatoko Shiotani
Satoko Shiotani
SOShinji Ohno
Shinji Ohno
It is unclear whether individualized treatments based on biological factors have improved the prognosis of recurrent breast cancer. The purpose of this study is to evaluate the survival improvement of patients with recurrent breast cancer after the introduction of third generation aromatase inhibitors (AIs) and trastuzumab.

2 August 2007 in Gene Therapy
Verified
Journal Article
Open access
PDF file
SSS Shiotani
S Shiotani
MSM Shimada
M Shimada
ATA Taketomi
A Taketomi
YSY Soejima
Y Soejima
TYT Yoshizumi
T Yoshizumi
YMY Maehara
Y Maehara
In the transplant surgery, reactive oxygen species (ROS) from the reperfused tissue cause ischemia-reperfusion injury, resulting in the primary graft failure. We have recently reported that Rho-kinase, an effecter of the small GTPase Rho, plays an important role in the ROS production in the hyperacute phase of reperfusion; however, the sources and mechanisms of the ROS production remain to be elucidated. The aim of this study was to investigate the source of ROS production with a special reference to Rho-kinase to develop a new strategy against ischemia-reperfusion injury. In an in vivo rat model of liver transplantation, Kupffer cells in the graft were depleted using liposome-encapsulated dichloromethylene diphosphonate to examine the source of ROS production. The effect of adenoviral-mediated overexpression of a dominant-negative Rho-kinase (AdDNRhoK) in hepatocytes in the graft was also examined. Kupffer cells were not involved in the ROS production, whereas the AdDNRhoK transfection to hepatocytes significantly suppressed the ROS production. Furthermore, the ROS production was dose-dependently inhibited by apocynin, an NADPH oxidase inhibitor. Expression of DNRhoK also suppressed the release of pro-inflammatory cytokines, and ameliorated the lethal liver injury with a significant prolongation of the survival. These results suggest that the Rho-kinase-mediated pathway plays a crucial role in the ROS production through NADPH oxidase in hepatocytes during the hyperacute phase of reperfusion in vivo. Thus, Rho-kinase in hepatocytes may be a new therapeutic target for the prevention of primary graft failure in liver transplantation.

9 July 2003
Verified
Journal Article
Closed access
KHKoji Hashimoto
Koji Hashimoto
MSMitsuo Shimada
Mitsuo Shimada
TSTaketoshi Suehiro
Taketoshi Suehiro
YSYuji Soejima
Yuji Soejima
RMRyosuke Minagawa
Ryosuke Minagawa
KSKeizo Sugimachi
Keizo Sugimachi